[2] In the interest of promoting the effective development of drugs, the main focus of his work is optimizing pharmacological models, the design of clinical studies, and data analysis and interpretation in the field of population pharmacokinetics.
To some extent, this was a challenge to the widely accepted dose/effect concept in pharmacology and toxicology at the time which assumed that the exposure/dose of a drug or a toxin is related to the effects on the patient, beneficial or toxic.
[5] Aarons has defined pharmacokinetics (PK) as the study of the complex chain of events that links a dose of drugs administered to a patient and the expected effect or response.
"[8] A later paper co-authored by Aarons, reviews the different approaches to optimal design of population pharmacokinetic and pharmacodynamic experiments and notes that some of the options may raise concerns at to their practicality.
"[12] In 2011 Aaron was part of a team that critiqued the then two-fold method of assessing drug-drug interaction and proposed that there would be less bias if predictions were made using a wider range of data collected and the allowance of variability was included in the process.
"[14] Aarons had collaborated on earlier research published in 2008 used physiologically based pharmacokinetic modelling (PBPK) to "evaluate the potential CYP3A4 inhibitory effect of a drug in development.